TRANSDERM SCOP (scopolamine)
Transderm Scop is an anticholinergic indicated for the prevention of nausea and vomiting in adults. It is specifically used to prevent motion sickness and post-operative nausea and vomiting (PONV) associated with recovery from anesthesia, surgery, and opiate analgesia. The transdermal system is designed to be applied before the onset of triggers to ensure efficacy.
How TRANSDERM SCOP Works
Scopolamine is a belladonna alkaloid that acts as a competitive inhibitor at postganglionic muscarinic receptor sites in the parasympathetic nervous system. It also acts on smooth muscles that respond to acetylcholine. Centrally, it is believed to prevent nausea by blocking cholinergic transmission from the vestibular nuclei to higher centers in the CNS and from the reticular formation to the vomiting center.
Development Insights
Details
- Status
- Prescription
- First Approved
- 1979-12-31
- Routes
- TRANSDERMAL
- Dosage Forms
- SYSTEM
TRANSDERM SCOP Approval History
What TRANSDERM SCOP Treats
4 indicationsTRANSDERM SCOP is approved for 4 conditions since its original approval in 1979. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Nausea
- Vomiting
- Motion Sickness
- Post-Operative Nausea and Vomiting
TRANSDERM SCOP Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to TRANSDERM SCOP
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
12 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT04999449 | STUDY02001115 | Ph 1 | completed | Nebulizer Delivery of Intranasal Scopolamine |
| NCT06014385 emo_to2 | 2000034723 000 | Ph 1 | withdrawn | PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor |
| NCT04211961 SCOPE-BD results posted | NUIG-2017-002 2017-003112-39 | Ph 2 | completed | Scopolamine in Bipolar Depression |
| NCT04666701 | EMS1319 - ESCÓCIA | Ph 2 | withdrawn | Efficacy and Safety of Escócia Association in the Treatment of Acute Pain |
| NCT03988530 | DPI-386-MS-24 | Ph 3 | completed | Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects |
| NCT01900301 | MH101359-01 | Ph 1 | completed | Generalization of Extinction Learning |
| NCT02918266 results posted | TAK-071-1002 U1111-1184-2278 | Ph 1 | terminated | TAK-071 Scopolamine-Induced Cognitive Impairment Study |
| NCT03131050 SCE | Scopolamine i.m. | Ph 4 | completed | Effectiveness Study of Scopolamine Combined With Escitalopram in Patients With MDD |
| NCT01213355 | B2081009 | Ph 1 | completed | Scopolamine Challenge Study |
| NCT02155309 results posted | NAMRUD.2013.0004 | Ph 2, Ph 3 | terminated | Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray |
| NCT01312844 results posted | 2009P002288 | Ph 2 | terminated | A Study of the Use of IV Scopolamine to Augment the Efficacy of Electroconvulsive Therapy (ECT) |
| NCT02051335 results posted | ROF-ALZ_102 2012-002089-11, U1111-1151-7178 | Ph 1 | completed | Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
TRANSDERM SCOP FDA Label Details
Indications & Usage
FDA Label (PDF)TRANSDERM SCOP is indicated for the treatment of Nausea; Vomiting; Motion Sickness; Post-Operative Nausea and Vomiting.
Track TRANSDERM SCOP with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment